Jagdish Butany, MBBS, MS, FRCPC, Department of Pathology, Toronto General Hospital, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ...

Jagdish Butany, MBBS, MS, FRCPC, Department of Pathology, Toronto General Hospital, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete presents with extreme ... Three athletes were diagnosed with a cardiomyopathy (0.4% prevalence); ...

Opens in a new tab or window CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or stabilize the structure and function of the ...

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...